Authors

Hanna J. Khoury, Winship Cancer Institute of Emory University
Tao Wang, Medical College of Wisconsin
Michael T. Hemmer, Medical College of Wisconsin
Daniel Couriel, Utah Blood and Marrow Transplant
Amin Alousi, The University of Texas MD Anderson Cancer Center
Corey Cutler, Dana-Farber Cancer Institute
Mahmoud Aljurf, King Faisal Specialist Hospital Center & Research
Joseph H Antin
Mouhab Ayas
Minoo Battiwalla, National Heart, Lung and Blood Institute-NIH
Jean-Yves Cahn, University Hospital, Grenoble
Mitchell Cairo, New York Medical College
Yi-Bin Chen, Massachusetts General Hospital
Robert Peter Gale, Imperial College London
Shahrukh Hashmi, Mayo Clinic Rochester; King Faisal Specialist Hospital Center & Research
Robert J. Hayashi, Washington University School of Medicine in St. Louis
Madan Jagasia, Vanderbilt University Medical Center
Mark Juckett, University of Wisconsin Hospital and Clinics
Rammurti T. Kamble, Baylor College of Medicine
Mohamed Kharfan-Dabaja, H. Lee Moffitt Cancer Center and Research Institute
Mark Litzow, Mayo Clinic Rochester
Navneet Majhail, Cleveland Clinic Taussig Cancer Institute
Alan Miller, Baylor College of Medicine
Taiga Nishihori, H. Lee Moffitt Cancer Center and Research Institute
Muna Qayed, Emory University School of Medicine
Helene Schoemans, University Hospital of Leuven
Harry C. Schouten, Academische Ziekenhuis
Gerard Socie, Hopital Saint Louis
Jan Storek, University of Calgary
Leo Verdonck, Isala Clinics Zwolle
Ravi Vij, Washington University School of Medicine
William A. Wood, University of North Carolina
Lolie Yu, Children’s Hospital/Louisiana State University Medical Center
Rodrigo Martino, Hospital de la Santa Creu I Sant Pau
Matthew Carabasi, Thomas Jefferson UniversityFollow
Christopher Dandoy, Cincinnati Children’s Hospital Medical Center
Usama Gergis, New York Presbyterian Hospital/Weill Cornell Medical Center
Peiman Hematti, University of Wisconsin Hospital and Clinics
Melham Solh, Northside Hospital, Atlanta
Kareem Jamani, University of Calgary
Leslie Lehmann, Dana Farber Cancer Institute, Boston Children’s Hospital
Bipin Savani, Vanderbilt University Medical Center
Kirk R. Schultz, British Columbia’s Children’s Hospital, The University of British Columbia
Baldeep M. Wirk, Seattle Cancer Care Alliance
Stephen Spellman, CIBMTR (Center for International Blood and Marrow Transplant Research)
Mukta Arora, University of Minnesota Medical Center
Joseph Pidala, H. Lee Moffitt Cancer Center and Research Institute

Document Type

Article

Publication Date

4-30-2017

Comments

This article has been peer reviewed. It is the author’s final published version in Haematologica

Volume 102, Issue 5, April 2017, Pages 958-966.

The published version is available at DOI: 10.3324/haematol.2016.156356. Copyright © Khoury et al.

Abstract

A cute graft-versus-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft-versus-host disease. We examined outcome following diagnosis of grade II-IV acute graft-versus-host disease according to time period, and explored effects according to original graft-versus-host disease prophylaxis regimen and maximum overall grade of acute graft-versus-host disease. Between 1999 and 2012, 2,905 patients with acute myeloid leukemia (56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%) received a sibling (24%) or unrelated donor (76%) blood (66%) or marrow (34%) transplant and developed grade II-IV acute graft-versus-host disease (n=497 for 1999-2001, n=962 for 2002-2005, n=1,446 for 2006-2010). The median (range) follow-up was 144 (4-174), 97 (4-147) and 60 (8-99) months for 1999-2001, 2002-2005, and 2006-2010, respectively. Among the cohort with grade II-IV acute graft-versus-host disease, there was a decrease in the proportion of grade III-IV disease over time with 56%, 47%, and 37% for 1999-2001, 2002-2005, and 2006-2012, respectively (P

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

Included in

Hematology Commons

Share

COinS